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proteins in the speciﬁc DNA/protein complex were identiﬁed by
mass spectrometry. siRNAs speciﬁc for p130cas and Hsp90 were
transfected, alone or in combination, into L-OA chondrocytes,
and the cells were incubated in the absence or presence of IL-1β
(100 pg/ml). Total RNA was extracted and processed for real-
time PCR with primers speciﬁc for the MMP-1, -2, -3, -9, -13 and
-14 genes. MMP-1 and -13 protein production was determined
by speciﬁc ELISAs.
Results: Mass spectrometry data revealed the presence of the
Hsp90 protein in the L-OA gel shift complex. siRNA experiments
on L-OA chondrocytes showed that p130cas and Hsp90 silenc-
ing signiﬁcantly increased the expression of MMP-13 (3.5 fold;
p<0.0001, and 1.8 fold; p<0.05, respectively) and, to a lesser ex-
tent, MMP-1 (2.2 fold; p<0.0001, and 1.6 fold; p<0.05), whereas
NMP4 showed no effect. These results point to an in vivo in-
hibitory role of p130cas and Hsp90 on these MMPs. The expres-
sion of MMP-2, -3, -9 and -14 was not affected by either factor.
Interestingly, the double silencing Hsp90/p130cas produced an
additive effect on MMP-13 expression (4.9 fold; p<0.0001), while
the effect on MMP-1 was minimal (2.3 fold; p<0.005). MMP-13
and MMP-1 protein levels are reminiscent of the expression pat-
tern. The presence of IL-1β with the p130cas-silenced cells, and
to some extent with the Hsp90-silenced cells, further stimulated
MMP-13 expression, suggesting that in vivo the presence of
these factors prevents a maximal stimulation by IL-1β.
Conclusions: This study identiﬁes the intracellular proteins
p130cas and Hsp90 as inhibitors of MMP-13 expression in L-
OA chondrocytes, and demonstrates the complexity of MMP-13
regulation. Studies are underway to determine if p130cas and
Hsp90 act independently or in cooperation.
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RESISTIN IS ELEVATED FOLLOWING TRAUMATIC JOINT
INJURY AND CAUSES MATRIX DEGRADATION AND
RELEASE OF INFLAMMATORY CYTOKINES FROM
ARTICULAR CARTILAGE IN VITRO
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Purpose: Determine if resistin is present in the joint following
joint injury and in primary osteoarthritis (OA) and to elucidate the
role of resistin in cartilage inﬂammation and degradation in vitro.
Abstract 153 – Figure 1
Methods: The level of resistin was measured in paired synovial
ﬂuid and serum samples from patients following joint injury (ACL
or meniscus tear), primary OA, and non-injury/non-OA controls
using adipokine multiplex kits. Localization of resistin in joint tis-
sues was visualized by immunohistochemistry (IHC) in synovial
tissue and cartilage from OA, rheumatoid arthritis (RA), and
normal controls. Murine cartilage explants were treated with re-
combinant resistin for three days in culture. Release of cytokines
was assayed in the supernatants using a cytokine multiplex kit.
Inﬂammatory marker, PGE2, was measured in culture super-
natants by ELISA. Matrix degradation was visualized in Toluidine
Blue stained cartilage sections and quantiﬁed by measuring re-
lease of sulfated GAG (sGAG) to the culture media using the
dimethylmethylene blue (DMMB) dye assay.
Results: Resistin was detected in synovial ﬂuid and serum
samples immediately after joint meniscus and ligament injury and
in the early stage of OA. The level of resistin in both synovial ﬂuid
and serum declined with increasing time after injury from 3000
pg/ml to 900 pg/ml in synovial ﬂuid and 8550 pg/ml to 5200 pg/ml
in serum. Resistin protein was detected by IHC in macrophages
and mast cells in synovial tissue from both OA and RA patients.
Cartilage was negative for resistin staining in 3/3 OA and 2/3
RA samples. Cartilage explants treated in vitro with resistin at
10 µg/ml released increased levels of MCP-1, KC (functional
homolog of human IL-8), IL-6, and PGE2 compared to untreated
control cultures (Fig. 1). Resistin stimulated degradation and
release of sGAG from the cartilage extracellular matrix.
Conclusions: Resistin is present in the joint following injury and
in primary OA and causes the release of inﬂammatory markers
and cartilage matrix degradation in vitro. Inhibition of resistin in a




PROTEIN KINASE 2 MODULATES THE
CYTOKINE-INDUCED PRODUCTION OF MATRIX
METALLOPROTEASESAND THE PUTATIVE PAIN
MEDIATOR PGE2 IN HUMAN OSTEOARTHRITIC
CHONDROCYTES
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Purpose: Mitogen-activated protein kinase-activated protein
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kinase 2 (MK2) is one of several serine/threonine kinases down-
stream of p38 signalling and has been reported to mediate the
post-transcriptional regulation of TNF-α. However, at present,
little is known about the functional role of MK2 in mediating
the effects of p38 activation in human cells. In this study we
examined the role of MK2 in mediating the cellular response
to pro-inﬂammatory cytokines in human cells including primary
osteoarthritic (OA) chondrocytes
Methods: Primary chondrocytes were isolated by collagenase
digestion of cartilage from the knee joints of OA patients following
joint replacement surgery and cultured in monolayer. Transfec-
tion with MK2 siRNA or a non-targeting control siRNA (Applied
Biosystems) was achieved using lipid (Atugen). Gene expres-
sion was determined by Real time-PCR using Taqman probes.
Production of prostaglandin E2 (PGE2), and of matrixmetallopro-
teases 3 (MMP3) and MMP13 (collagenase 3) were measured
by ELISA
Results: We found that both TNF-α and IL-1 were capable of
inducing the phosphorylation of HSP27 (an MK2 substrate) in
HeLa cells and that this phosphorylation was inhibited by over-
expression of a dominant-negative form of MK2. Furthermore,
over-expression of this dominant negative form of MK2 signiﬁ-
cantly reduced the IL-1 and TNF-α mediated release of PGE2
over a 24h period (P<0.05). To investigate this further we ex-
amined the role of MK2 in isolated primary OA chondrocytes
from human OA knee joints. Transfection of siRNA antisense
resulted in a reduction in OA chondrocyte MK2 mRNA by 95%
after 48h, and a corresponding reduction of MK2 protein 72h
post-transfection. Transfection of OA chondrocytes with MK2
siRNA also reduced both basal PGE2 release (P<0.05) and
IL-1-induced PGE2 release (P<0.01). Importantly, we also found
that siRNA-induced knockdown of MK2 signiﬁcantly reduced both
basal and IL-1-induced MMP13 mRNA expression (P<0.01) and
IL-1 induced MMP13 and MMP3 protein release (P<0.05).
Conclusions: Our data reveal that MK2 is required for PGE2,
MMP3 and MMP13 release from OA chondrocytes. These ﬁnd-
ings suggest a role for MK2 in contributing to OA algesia and
OA joint structural deterioration by mediating the downstream
effects of p38 activation on PGE2 release and the expression
and release of catabolic proteases.
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PI3K REGULATES CHONDROCYTE DIFFERENTIATION
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Purpose: Endochondral ossiﬁcation, the process through which
long bones are formed, involves chondrocyte proliferation and
hypertrophic differentiation in the cartilage growth plate. These
processes are often recapitulated during osteoarthritis. Numer-
ous growth factors and hormones have been implicated in the
regulation of growth plate biology, however, less is known about
the intracellular signaling pathways involved. The purpose of our
study was to characterize the involvement of PI3K/Akt signaling
in cartilage development. We focused on the PI3K/Akt pathway
since is known as a major regulator of cellular proliferation,
differentiation and death in multiple cell types.
Methods: Employing an organ culture system of embryonic
mouse tibias and LY294002, a pharmacological inhibitor of PI3K
we compared the length of the tibiae, different zones of the
growth plate, between LY294002 treated bones and the con-
trol. Immunohistochemistry assays with antibodies for collagen
X, p57 and phosphorylated Akt were performed on sections
obtained from the two treatments. We then performed similar
experiments using long bones from Akt1 (main target of the
PI3K) KO and control mice. Using micro CT analysis, skeletons
of Akt1 KO and control mice were compared. Primary chondro-
cytes were isolated from long bones of E15.5 mouse embryos
and were treated with LY294002 or control for a few days, then
TUNEL staining for apoptosis and cell counts were performed.
RNA was isolated from primary chondrocytes after 24 hours of
culture in the presence of LY294002 or DMSO and hybridized to
Affymetrix gene chips. Pathways and functional categories regu-
lated by PI3K signaling were then identiﬁed using Bioinformatics
approaches.
Results: PI3K inhibition results in smaller proliferative and hy-
pertrophic zones of the growth plate, reduced area of p57 stain
and decreased cell numbers in primarychondrocyte cultures, in-
dicating that this pathway is required for maximal proliferation
and differentiation. TUNEL staining of primary chondrocytes also
showed an increased number of apoptotic cells in LY294002
treated cultures compared to controls.
From birth until adulthood, Akt1 KO mice are smaller than their
littermates and most of their long bones are 10% shorter than
in wild-type littermates. KO bones also show delayed growth
plate development (as shown by micro-CT) as well as delayed
formation of secondary ossiﬁcation centers. Similar to LY29400-
treated organ cultures, growth plates from Akt1-deﬁcient mice
display reduced length of hypertrophic zone. Microarray analyses
coupled to bioinformatics identiﬁed numerous target genes of
PI3K activity in chondrocytes as well as functional categories
controlled by this signaling pathway.
Conclusions: In summary, our data demonstrate an essential
role of PI3K signaling in endochondral bone growth and provide
insight into the involved molecular mechanisms.
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TISSUE INHIBITOR OF METALLOPROTEINASES-3
INDUCTION BY TRANSFORMING GROWTH FACTOR
BETA IN HUMAN CHONDROCYTES IS MEDIATED BY
SMAD SIGNALING
H. Qureshi, G. Ricci, M. Zafarullah
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Purpose: To study the role of Smad signaling pathway in
transforming growth factor beta induction of Tissue inhibitor of
metalloproteinases-3 (TIMP-3).
Methods: Normal human knee chondrocytes (Cambrex, Walk-
erville, MD) were grown in Differentiation Bullekit medium as
high-density short-term monolayer cultures. Cells were either
treated with various pharmacological inhibitors or tranfected with
negative control or Smad-speciﬁc siRNAs. Subsequently, cells
were stimulated with TGF-β. Knockdown of respective proteins
and effect on TIMP-3 was studied by Western blot analysis. Pro-
moter and deletion mutants were constructed and transfected
by a high-efﬁciency, modiﬁed Calcium phosphate method. Lu-
ciferase assays were also conducted to monitor the promoter
activity.
Results: TGF-β1-enhanced Smad2 phosphorylation and TIMP-3
protein expression could be inhibited by the Smad2/3 phosphory-
lation inhibitors, PD169316 and SB2023580 but not by an inactive
homologue, SB202474. Similarly, Smad2-speciﬁc siRNA-driven
Smad2 deﬁciency but not negative control siRNA also down-
regulated TIMP-3 induction. Speciﬁc inhibitor of Smad3 (SIS3)
and Smad3 siRNA but not negative control siRNA abolished
TGF-β induction of TIMP-3. Smad2 and -3 siRNAs also down
regulated TIMP-3 promoter-driven luciferase activities, suggest-
ing transcriptional regulation. SiRNA-driven co-Smad4 knock-
down abrogated TIMP-3 augmentation by TGF-β. In contrast,
suppression of inhibitory Smad7 had no effect on TIMP-3 in-
crease. TIMP-3 promoter deletion analysis revealed that -828
deletion retains the original promoter activity while -333 and -167
deletions display somewhat reduced activity.
Conclusions: Receptor-activated Smad2 and Smad3 and co-
